#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    MELAS syndrome Mucopolysaccharidosis I Inflammatory myofibroblastic tumour Immune thrombocytopenia Acute on chronic liver failure Pituitary-dependent Cushing's syndrome Cardiac sarcoidosis Myelin oligodendrocyte glycoprotein antibody-associated disease Fibrous dysplasia of bone Lennox-Gastaut syndrome Renal disorder Sickle cell disease Cytokine release syndrome Soft tissue necrosis Hyperphagia More trials…

    Learn about Rare Diseases

    Bronchopulmonary dysplasia – Treatment Haemolytic uraemic syndrome – Diagnostics Alveolar rhabdomyosarcoma – Trials in Disease Nodal marginal zone B-cell lymphoma Chondrosarcoma metastatic – Diagnostics Aicardi-Goutieres syndrome – Trials in Disease Pleural mesothelioma malignant – Trials in Disease Langerhans’ cell histiocytosis – Trials in Disease Activated PI3 kinase delta syndrome Marginal zone lymphoma refractory – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Munc-T3 Ly3473329 Eik1003 Atrasentan Hydrochloride Metyrapone ADX-324 Acou085 Ecoo6A Temocillin Sodium Eliglustat Tartrate Gsk4527226 Paclitaxel Obaluronate Guselkumab Allopurinol Sodium ICOTROKINRA Micronised Spironolactone Bendamustine Lorazepam Voclosporin Cefuroxime Sodium More therapies…

    Learn about Your Condition

    Atrial flutter Acoustic neuroma Vomiting Haematological malignancy Autism spectrum disorder Femoral neck fracture Endometrial cancer stage III Asymptomatic HIV infection Chronic fatigue syndrome Colorectal adenocarcinoma Oesophageal carcinoma Colitis Choroidal neovascularisation Mite allergy Partial lipodystrophy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Uniwersytecki Szpital Kliniczny W Bialymstoku

Uniwersytecki Szpital Kliniczny W Bialymstoku

Zurawia 14, Bialystok, 15-540, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study comparing cagrilintide and semaglutide versus tirzepatide in people with type 2 diabetes taking metformin or SGLT2 inhibitor

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Cagrilintide
    • Semaglutide
    • Tirzepatide
    Germany Greece Hungary Poland Romania Spain

  • A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

    Not recruiting

    3 1
    Investigated Diseases:
    • Cardiovascular disorder
    Investigated Drugs:
    • Cagrilintide
    • Semaglutide
    Bulgaria Denmark France Germany Ireland Italy +3

  • A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

    Not recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    • Chronic kidney disease
    Investigated Drugs:
    • Ziltivekimab
    Belgium Bulgaria Croatia Czechia Denmark Germany +12

  • A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

    Not recruiting

    3 1
    Investigated Diseases:
    • Acute myocardial infarction
    Investigated Drugs:
    • Ziltivekimab
    Bulgaria Czechia Denmark France Germany Greece +4

  • A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

    Not recruiting

    3 1
    Investigated Diseases:
    • Cardiac failure
    Investigated Drugs:
    • Ziltivekimab
    Austria Belgium Bulgaria Croatia Czechia Denmark +18

  • Study of VRDN-001 compared to placebo to evaluate safety and effectiveness in adults with chronic thyroid eye disease

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Sodium Chloride
    • Vrdn-001
    France Germany Hungary Italy Poland Spain

  • Evaluation of Ziltivekimab in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Ziltivekimab
    Bulgaria Czechia France Germany Greece Poland +1

  • Study on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Diabetic retinal oedema
    Investigated Drugs:
    • Eye103
    • Fluorescein Sodium
    • Ranibizumab
    Austria Croatia Czechia France Germany Hungary +6

  • Study on the Effectiveness and Safety of the VLA15 Vaccine for Preventing Lyme Disease in Healthy Individuals Aged 5 and Older

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Sodium Chloride Solution 0.9%
    Finland Germany The Netherlands Poland Sweden

  • Study on the Effectiveness and Safety of Brensocatib for Patients with Chronic Rhinosinusitis Without Nasal Polyps

    Not recruiting

    2 1 1
    Investigated Drugs:
    • BRENSOCATIB
    Belgium Bulgaria Czechia Denmark France Germany +5
Previous Page
1 … 6 7 8 9 10 … 16
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!